161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives

Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed on the membranes of prostate cancer cells. Lutetium-177 (177Lu)- labelled PSMA-targeted radioligand therapy (PRLT) is employed in treating metastatic castration-resistant prostate cancer (mCRPC) that no...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Liming Xiao, Ziyi Zhao, Rui Luo, Fucen Liu, Bosen Hu, Peng Zhao, Xia Yang, Zhengguo Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-01-01
Edice:	Frontiers in Oncology
Témata:	dosimetry lutetium-177 (177Lu) metastatic castration-resistant prostate cancer(mCRPC) prostate-specific membrane antigen (PSMA) PSMA-targeted radioligand therapy (PRLT) radiopharmaceuticals
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1743628/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!